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and  can  be  less  expensive  than  hospital‐based  intravenous  immunoglobulin  (IVIG)  in  treating  chronic 
inflammatory demyelinating polyneuropathy (CIDP) patients. This economic evaluation aims at comparing 
costs of SCIG vs  IVIG  for CIDP patients  in  Italy. A 1‐year model‐based cost‐minimization analysis basically 
populated  via  neurologists’  opinion was  undertaken  from  a  societal  perspective. Health  care  resources 
included  immunoglobulin; drugs for premedication and complications (rash, headache, and hypertension) 
management;  time  of  various  health  care  professionals;  pump  for  SCIG  self‐administration;  infusion 
disposables. Non‐health care resources encompassed transport and parking;  losses of working and  leisure 
time  for patients and caregivers. Unit or yearly costs  for  resources valuation were mainly obtained  from 
published sources. Costs were expressed in Euro (€) 2013. An extensive one‐way sensitivity analysis (OWSA) 
and  a  scenario  SA  tested  the  robustness of  the base  case  findings. Overall  costs per patient  amount  to 
€49,534.75 (SCIG) and €50,895.73 (IVIG); saving in favour of SCIG reaches €1360.98. For both SCIG and IVIG, 
the cost driver was immunoglobulin (94.06 vs 86.06 % of the overall costs, respectively). Sensitivity analyses 
confirmed  the  consistency  of  the  baseline  results.  SCIG may  be  a  cost‐saving  therapy  for  Italian  CIDP 
patients. 


























Consistently with  the societal standpoint, health care and non‐health care  resources were  identified and 
quantified based on neurologists’ opinion and research hypotheses (Table 1). 
Table 1: Resource identification and quantification 
Item SCIG IVIG Source 
Health care resources 
 Training for SCIG self-administration 
  Nurse time 





  Premedication – 
Antihystaminic 
(10 mg per os) 





  Immunoglobulin 960 g per yeara 960 g per yeara 
Experts’ 
opinion 
  GP consultation for recipes 2 per year 12 per year 
Experts’ 
opinion 
  LHA admittances for 
receiving immunoglobulin, 
disposable and self-infusion 





Item SCIG IVIG Source 
  LHA pharmacist time for 
delivering immunoglobulin, 
disposable and self-infusion 




  Number of administrations 96 per yearb 24 per yearc 
Experts’ 
opinion 
  Neurologist time – 0.50 h per administration 
Experts’ 
opinion 
  Nurse time – 1 h per administration 
Experts’ 
opinion 
  Self-infusion pump 
1 self-infusion 
pump 50 ml – 
Experts’ 
opinion 
  Disposables 






device 1 tubing 
 Follow-up 
  Neurologist time 
2 visits per 
year, 0.50 h 
each 




  Electromyography (12 




  Neurologist time for rash; 
headache; hypertension – 




  Other specialist time for 
rash; headache; 
hypertension – 




  Nurse time – 0.33 h for rash; Experts’ 
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Item SCIG IVIG Source 
headache; hypertension; 
0.25 h for difficult iv 
opinion 
  Drug for rash – 
Antihystaminic 
(10 mg per os for 
1 day)e corticosteroid 
(4 mg iv for 1 day) 
Experts’ 
opinion 
  Drug for headache – 
paracetamol (2 g 
suppositories per diem 
for 2.5 days) 
Experts’ 
opinion 
  Drug for hypertension – 
Amlodipine besylate 
(5 mgper os for 1 day) 




Non-health care resources 
 Training for SCIG self-administration 
  Transport 









  Therapy       
  Transport 




  Parking 





  Transport – 12 km per administration 
Experts’ 
opinion 






Item SCIG IVIG Source 
hypotheses 
 Follow-up 
  Transport 
12 km per 
follow-up visit 12 km per follow-up visit 
Research 
hypotheses 
  Parking 
1.5 h per 




  Parking – 
1.30 h rash; headache; 







 Training for SCIG self-administration 
  Patient 




  Caregiverg 





  Patients time (admittance 
to GP surgery) 
1 h per 
admittance 1 h per admittance 
Research 
hypotheses 
  Patients time (admittance 
to LHA) 





  Patient – 5 h per administration 
Experts’ 
opinion 






Item SCIG IVIG Source 
  Patient 
3 h per follow-
up visit 3 h per follow-up visit 
Experts’ 
opinion 
  Caregiverg,h 
3 h per follow-




  Patient – 
0. 80 h rash; headache; 






  Caregiverh – 
0. 80 h rash; headache; 






Leisure time losses 
 Administration 









dProportion  of  complications  per  IVIG  administration:  rash:  0.25;  headache:  0.50;  hypertension:  0.50; 
difficult iv: 0.40. Patients may report more than one complication 
eProportion of IVIG patients needing 10 mg per os for further 7 days: 0.10 
fProportion of employed patients and housewives  for SCIG and  IVIG patients: 0.46 and 0.14,  respectively. 
The same proportions were assumed for caregivers, too 
fProportion  of  SCIG  patients  needing  caregivers’  support  (training  for  self‐administration  and  follow‐up 
visits): 0.04 
hProportion  of  IVIG  patients  needing  caregivers’  support  (administration  sessions;  follow‐up  visits  and 
complications): 0.40 
 






Assuming  a  patient weight  of  80  kg,  a monthly  infusion  scheme  of  1  g  of  immunoglobulin  per  kg was 
considered. SCIG patients were assumed to self‐administer 10 g of immunoglobulin twice per week (i.e. 96 
administrations per year), and  IVIG patients  to  receive 40 g of  immunoglobulin  twice per month  in  two 
subsequent days (i.e. 24 administrations per year) in hospital setting. 
Non‐health  care  resources encompassed  transport  and parking,  as well as  losses of working and  leisure 
time for patients and caregivers. 
Distance  back  and  forth  between  patients’  home  and  hospital  (LHA) was  estimated  at  12  (6)  km  and 
travelled  by  car,  whereas  a  walking  distance  of  2  km  between  patients’  home  and  GP  surgery  was 
considered. 
Parking duration was assumed to be 0.5 h  longer than patients and caregivers’ time  loss, considering that 







accessing GP  surgery  for  recipes  concerning neurologist  visits,  immunoglobulin  infusions,  and  follow‐up; 
accessing LHA  for receiving  immunoglobulin, disposables, and self‐infusion pump  (SCIG only); undergoing 











Item SCIG IVIG Source 
Health care sector costs 
 Nurse (per h) 21.24 21.24 [9, 28] 
 Neurologist (per h) 55.90 55.90 [9, 28] 
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Item SCIG IVIG Source 
 Other specialist (per h) – 55.90 [9, 28] 
 GP (per consultation) 21.71 21.71 [9, 28] 
 LHA pharmacist (per h) 39.27 – [12, 28] 
 Immunoglobulin (per g) 48.54 45.63 
Weighted average tender price negotiated 
between pharmaceuticals and five Italian 
Regions, 1st quarter 2013; [18] 
 Antihystaminic 
(10 mg per os) – 0.22 [15] 
 Corticosteroid (4 mg vial 
iv) – 0.55 [15] 
 Paracetamol (1 g 
suppository) – 0.46 [15] 
 Amlodipine besylate 
(5 mg per os) – 0.13 [15] 
 Furosemide (20 mg vial 
iv)   0.41 [15] 
 Disposables (per 
administration) – 19.88 [9, 28] 
 Electromyography(12 
nerves) 123.96a 123.96a [16] 
Patients and their family costs 
 Out-of-pocket expenses 
  Transport (per km) 0.26b 0.26b [14] 
  Parking (per h) 1.50 1.50 
Average hourly cost in three Northern 
Italy towns 
 Productivity losses 
  Average gross cost (per 
h)—employed 30.20 30.20 [25–28] 
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Item SCIG IVIG Source 
  Average gross cost (per 
h)—housewife 14.34 14.34 [22, 23, 26–28] 
 Leisure time losses 
  Average net cost (per 
h)—employed c 13.86 – [25, 28] 
Other sectors costs 
 Self-infusion pump (per 
year) 202 – Average market price for Italy 
 Disposables (per 












disposables  (SCIG  only),  as  in  Italy  these  items  are  usually  provided  and  funded  by  pharmaceuticals 
producing immunoglobulin, with no charge for hospital, LHA or patient. 
Monetary  values  for  resources different  from patients,  caregivers,  and housewives’  time were obtained 
from published  sources  [9, 12–15], estimated using  tariffs  for  funding health  care providers  in  Italy  [16] 
assuming  that  they  were  a  good  proxy  of  the  actual  costs  [17],  or  retrieved  via  ad  hoc  researches 
(immunoglobulin; parking; self‐infusion pump and disposables for SCIG). 
Immunoglobulin was valued using the average tender price per gram negotiated between pharmaceuticals 
and  five  Italian Regions  (North East: 1; North West: 1; Centre: 1; South: 2) during  the 1st quarter 2013, 
weighted  for  the  relative population  [18]  to  take  into account potential differences  in  the exposition  to 
immunoglobulin at local level. 
Consistently with the useful life for a SCIG self‐infusion pump, a 5‐year straight‐line depreciation approach 
[10] was adopted  for calculating  the yearly cost of  this device. Therefore,  the yearly cost of a SCIG  self‐





No co‐payment  for drugs or health care services was  included among out‐of‐pocket expenses, as  in  Italy 
CIDP patients can apply for a disease‐based exemption [19]. 
Time off paid work (leisure time) was valued using the average gross (net) annual wage rate for different 
professional  categories, whereas housewives’  time was  costed using  the  average  gross hourly  cost of  a 
patient companion [20–27]. 
All  costs were  expressed  in  Euro  (€)  2013  and  updated  to  this  year  according  to  proper  inflation  rates 
whenever necessary [28]. 
Yearly costs for patient on SCIG or IVIG and their difference were calculated. 














95 % CI 
calculation 
95 % CI 
Patient weight 80 10 8.00 Gamma 65.09;96.42 
Number of administrations (per year) 
 SCIG 96 10 9.60 Gamma 78.11;115.71 
 IVIG 24 10 2.4 Gamma 19.53; 28.93 
 Number of LHA 
admittances (per year)a 4 24 0.96 Gamma 2.35; 6.09 
Hours per administration 
 SCIG 1.25 10 0.13 Gamma 1.02;1.51 









95 % CI 
calculation 
95 % CI 
 Kmb 12 40 4.80 Gamma 4.52;23.08 
 Cost (per km) 0.26 10 0.03 Normal 0.21;0.32 
 Parking cost (per h) 1.50 10 0.15 Normal 1.21;1.79 
Average gross cost (per h) 
 Employed 29.24 10 2.92 Normal 23.51;34.97 
 Housewife 15.12 10 1.51 Normal 12.16;18.09 
Average net cost (per h) 
 Employed 13.45 10 1.34 Normal 10.81;16.08 
 Nurse cost (per h) 21.24 10 2.12 Normal 17.08;25.40 
 Neurologist cost (per 
h) 55.90 10 5.59 Normal 44.94;66.85 
 Other specialist cost 
(per h) 55.90 10 5.59 Normal 44.94;66.85 
 LHA pharmacist cost 
(per h) 39.27 10 3.93 Normal 31.57;46.97 
 Cost of GP (per 
consultation) 21.71 10 2.17 Normal 17.46;25.97 
Cost of immunoglobulin (per g) 
 SCIG 48.54 0.03 1.46 Normal 45.68;51.39 
 IVIG 45.63 0.03 1.37 Normal 42.94;48.31 
 Cost of self-infusion 
pump (per year)a 202 10 20.20 Normal 162.41;241.59 
Cost of disposables (per administration) 
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95 % CI 
calculation 
95 % CI 
 SCIG 10.16 10 1.02 Normal 8.17;12.15 
 IVIG 19.88 10 1.99 Normal 15.98;23.78 
 Cost of 
electromyography (12 
nerves) 123.96 10 12.40 Normal 99.66;148.26 
 Proportion of 
employed (patients and 
caregivers) 0.46 – 0.05c Beta 0.36;0.56 
 Proportion of 
housewives (patients 
and caregivers) 0.14 – 0.03c Beta 0.08;0.21 
Proportion of patients needing caregivers’ support 
 SCIG 0.04 – 0.02c Beta 0.01;0.09 
 IVIG 0.40 – 0.05c Beta 0.31;0.50 
 Proportion of rashd 0.25 – 0.04c Beta 0.17;0.34 
 Proportion of 
headached 0.50 – 0.05c Beta 0.40;0.60 
 Proportion of 
hypertensiond 0.50 – 0.05c Beta 0.40;0.60 
 Proportion of difficult 
ivd 0.40 – 0.05c Beta 0.31;0.50 
CV  coefficient  of  variation  (CV  =  SE/Point  estimate),  GP  general  practitioner,  IVIG  intravenous 













estimate with  the  lower  and  the  upper  limits  of  95 %  CI while  keeping  the  other  parameters  at  their 
baseline  levels [10, 11]—was carried out on: hourly cost of health care professionals, patients, caregivers, 
and  parking;  cost  of  immunoglobulin,  disposables,  self‐infusion  pump  for  SCIG,  and  electromyography; 
patient weight; number of administrations per year and  their duration; number of  LHA admittances per 









Overall costs per patient amount  to €49,534.75 and €50,895.73  for SCIG and  IVIG, respectively; saving  in 
favour of SCIG reaches €1,360.98 (Table 4). 
Table 4: Base case analysis—cost‐minimization analysis (costs in €2013) 
Item SCIG (%) (A) IVIG (%) (B) Saving for SCIG (%) (B−A) 
Health care sector costs       
 Training for SCIG self-administration       
  Nurse time 106.19 (0.21) −(0.00) −106.19 (−7.80) 
 Therapy       
  Premedication −(0.00) 18.44 (0.04) 18.44 (1.35) 







  GP consultation for recipes 43.43 (0.09) 260.57 (0.51) 217.14 (15.95) 
  LHA pharmacist time for delivering 
immunoglobulin and disposable 52.36 (0.11) −(0.00) −52.36 (−3.85) 
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Item SCIG (%) (A) IVIG (%) (B) Saving for SCIG (%) (B−A) 
 Administration       
  Neurologist time −(0.00) 670.75 (1.32) 670.75 (49.28) 
  Nurse time −(0.00) 509.72 (1.00) 509.72 (37.45) 
  Disposables −(0.00) 477.12 (0.94) 477.12 (35.06) 
 Follow-up       
  Neurologist time 55.90 (0.11) 55.90 (0.11) −(0.00) 
  Electromyography 123.96 (0.25) 123.96 (0.24) −(0.00) 
 Complications       
  Neurologist time −(0.00) 838.43 (1.65) 838.43 (61.61) 
  Other specialist time −(0.00) 41.92 (0.08) 41.92 (3.08) 
  Nurse time −(0.00) 258.05 (0.51) 258.05 (18.96) 
  Drug for rash −(0.00) 5.51 (0.01) 5.51 (0.41) 
  Drug for headache −(0.00) 27.60 (0.05) 27.60 (2.03) 
  Drug for hypertension −(0.00) 6.52 (0.01) 6.52 (0.48) 




(92.53) 119.74 (8.80) 
Patients and their family costs       
 Out-of-pocket expenses       
  Training for SCIG self-administration       
   Transport 6.35 (0.01) −(0.00) −6.35 (−0.47) 
   Parking 9.00 (0.02) −(0.00) −9.00 (−0.66) 
  Therapy       
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Item SCIG (%) (A) IVIG (%) (B) Saving for SCIG (%) (B−A) 
   Transport 3.17 (0.01) −(0.00) −3.17 (−0.23) 
   Parking 4.50 (0.01) −(0.00) −4.50 (−0.33) 
  Administration       
   Transport −(0.00) 76.19 (0.15) 76.19 (5.60) 
   Parking −(0.00) 126.00 (0.25) 126.00 (9.26) 
  Follow-up       
   Transport 6.35 (0.01) 6.35 (0.01) −(0.00) 
   Parking 4.50 (0.01) 4.50 (0.01) −(0.00) 
  Complications       
   Parking −(0.00) 71.55 (0.14) 71.55 (5.26 %) 
 Productivity losses       
  Training for SCIG self-administration       
   Patient 139.75 (0.28) −(0.00) 
−139.75 
(−10.27) 
   Caregiver 5.59 (0.01) −(0.00) −5.59 (−0.41) 
  Therapy       
   Patients/caregiver time (access to GP 
surgery) 31.06 (0.06) 186.34 (0.37) 155.28 (11.41) 
   Patients/caregiver time (access to 
LHA) 77.64 (0.16) −(0.00) −77.64 (−5.70) 
  Administration       





   Caregiver −(0.00) 745.36 (1.46) 745.36 (54.77) 
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Item SCIG (%) (A) IVIG (%) (B) Saving for SCIG (%) (B−A) 
  Follow-up       
   Patient 93.17 (0.19) 93.17 (0.18) −(0.00) 
   Caregiver 3.73 (0.01) 37.27 (0.07) 33.54 (2.46) 
  Complications       
   Patient −(0.00) 421.59 (0.83) 421.59 (30.98) 
   Caregiver −(0.00) 168.64 (0.33) 168.64 (12.39) 
 Leisure time losses       
  Administration 
996.94 
(2.01 %) −(0.00) 
−996.94 
(−73.25) 







Other sectors costs       
 Administration       
  Infusion pump 202 (0.41) −(0.00) 
−202.00 
(−14.84) 
  Disposables 975.36 (1.97) −(0.00) 
−975.36 
(−71.67) 

















SCIG  (2.79 vs 7.47 % of  the overall costs,  respectively). Saving  in  favour of SCIG  is mainly explained by a 
17 
 








OWSA—cost‐minimization analysis  (savings  in €2013).  IVIG  intravenous  immunoglobulin; OWSA one‐way 
sensitivity analysis; SCIG subcutaneous immunoglobulin; 95 % CI 95 % confidence interval 
Consistently with  the base  case  results,  changing  the  cost per  gram of  immunoglobulin has  the highest 
impact on  the baseline  findings. Replacing  the base  case  cost per gram  for SCIG with  the 95 % CI  limits 
remarkably influences savings for SCIG (€4,100.64 or +201.30 % vs baseline results; −€1,378.69 or −201.30 
% vs baseline results). Differences against base case saving  for SCIG are slightly  lower when  the cost per 
gram  for  IVIG  is changed  in  the same  fashion  (€3,936.42 or +189.23 % vs baseline  results; −€1,214.47 or 
−189.23 % vs baseline results). 





Conversely, changing  in  the  same way  the number of SCIG  self‐administrations per year has only a mild 




hospital  or  patient  and  their  family  budget,  the  overall  saving  in  favour  if  SCIG would  remain  unvaried 
(€1,360.98) (Table 5). 
Table 5: Scenario SA—Cost‐minimization analysis (costs in €2013) 
Item SCIG (%) (A) IVIG (%) (B) Saving for SCIG (%) (B−A) 
Base case analysis 





(92.53) 119.74 (8.80) 
 Total patients and their 
family costs 1,381.75 (2.79) 3,800.35 (7.47) 2,418.60 (177.71) 
 Total other sectors costs 1,177.36 (2.38) −(0.00) −1,177.36 (−86.51) 




(100.00) 1,360.98 (100.00) 
Scenario sensitivity analysis—cost for self- infusion pump and disposables for SCIG shifted from 
pharmaceuticals to hospital budget 





(92.53) −1,057.62 (−77.71) 
 Total patients and their 
family costs 1,381.75 (2.79) 3,800.35 (7.47) 2,418.60 (177.71) 
 Total other sectors costs −(0.00) −(0.00) −(0.00) 




(100.00) 1,360.98 (100.00) 
Scenario sensitivity analysis—cost for self- infusion pump and disposables for SCIG shifted from 
pharmaceuticals to patient and their family budget 





(92.53) 119.74 (8.80) 
 Total patients and their 2,559.11 (5.17) 3,800.35 (7.47) 1,241.24 (91.20) 
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Item SCIG (%) (A) IVIG (%) (B) Saving for SCIG (%) (B−A) 
family costs 









analysis  confirms  that,  given  the  same  effectiveness  [8,  9],  SCIG  seems  cost  saving  when  compared 
withIVIG. If only half of the prevalent 2,126 CIDP patients estimated for Italy [7, 18] were prescribed SCIG 
instead of IVIG, saving for society and health care sector would reach €1.45 and €0.13 million, respectively. 
It  is worth noting  that, even without adjusting  for  inflation,  the base case saving  in  favour of SCIG could 
have been  fourfold  if  the  standard  cost per  gram of  IVIG  reported by  the  Italian National Blood Centre 
(€49.95, 2011 values) [33] instead of the weighted average tender price had been used. 





The  results of our  research  support  the  evidence  that preferring  SCIG  vs  IVIG  generates  saving  also  for 
hospital.  Interestingly,  saving at hospital  level  is due  to a  sort of  “informal partnership” between health 





saved  from  moving  back  and  forth  between  home  and  hospital  for  immunoglobulin  administration, 
improves SCIG patients’ health‐related quality of life (HRQoL) is still debated [9, 34] and shall benefit from 
further investigations on samples of patients of adequate size. 
This  economic  evaluation  has  two  main  limitations.  Firstly,  due  to  a  remarkable  lack  of  patient  level 
comparative  research on  the health economics of SCIG vs  IVIG  in CIDP, our cost‐minimization analysis  is 
based on a model that relied heavily on experts’ opinions about resource consumption and loss induced by 
CIDP  management.  However,  modelling  was  previously  utilized  for  the  economic  evaluation  of  CIDP 





The second  limitation  rests on  the  fact  that  the health care professionals whose qualified opinions were 
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